A state-of-the-art campus designed to turn scientific ambition into breakthroughs for people with cancer

For more than two decades, Pfizer has pushed the boundaries of cancer care, developing medicines that have helped transform treatment for some of the world’s most challenging cancers. That progress continues to fuel an ambition to keep expanding what’s possible – an ambition brought to life in San Diego, where a new state-of-the-art campus has been purpose-built to help advance science and accelerate the next generation of cancer breakthroughs.

Pfizer San Diego is designed to bolster discovery by bringing critical scientific capabilities together in one place – strengthening end-to-end R&D and powering the next chapter of Pfizer Oncology. The new facility includes specialized laboratories serving as hubs for small‑molecule capabilities, while also supporting a broad pipeline of innovative biologics.

“Pfizer has set an ambitious goal to deliver eight breakthrough cancer medicines by 2030,” said Jeff Legos, Chief Oncology Officer at Pfizer. “That goal is grounded in an R&D strategy focused on speed and breadth, and on bringing science to life in ways that can make a meaningful difference for people living with cancer. Our new San Diego campus is a testament to our investment in the future of Pfizer Oncology R&D – helping turn innovation into breakthroughs that can truly change lives.”

Speed means compressing timelines across R&D, from early discovery through to clinical development – so promising ideas can move forward more quickly. Breadth reflects the ability to apply the right scientific approach across modalities to each challenge cancer presents. Together, this way of working is designed to move promising ideas toward patients with greater clarity and momentum.

Spanning approximately 230,000 square feet, Pfizer San Diego is a modern R&D environment focused on collaboration and pace. The scale is designed to match the complexity of oncology research – supporting teams as they move from hypothesis to insight to action.

“When the environment supports deeper thinking and faster learning, science can move forward quickly,” said Jeff Settleman, Chief Scientific Officer for Pfizer Oncology. “The San Diego campus is designed to foster that environment – enabling the pursuit of bold new ideas, faster cycles of learning, and better-informed decision-making.”

Approximately 600 scientists and staff will work at the campus, uniting experts in discovery, biology, translational science, and early development in one location. Together, the concentration of expertise and the design of the campus reflect a long‑term investment in how science is done - supporting faster learning, stronger decision‑making, and a more efficient pathway between discovery and patient impact.

The San Diego campus – and the scientists who bring it to life – reflect Pfizer Oncology’s determination to redefine what’s possible in cancer care, turning scientific investment into progress that matters.